Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of nivolumab plus ipilimumab with tyrosine kinase inhibitors as first-line therapies for metastatic renal-cell carcinoma: a multicenter retrospective study.
Kido K, Hatakeyama S, Numakura K, Tanaka T, Oikawa M, Noro D, Hosogoe S, Narita S, Inoue T, Yoneyama T, Ito H, Nishimura S, Hashimoto Y, Kawaguchi T, Habuchi T, Ohyama C. Kido K, et al. Int J Clin Oncol. 2021 Jan;26(1):154-162. doi: 10.1007/s10147-020-01797-5. Epub 2020 Oct 16. Int J Clin Oncol. 2021. PMID: 33067647
Efficacy and safety of first-line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study.
Tanaka T, Hatakeyama S, Numakura K, Kido K, Noro D, Oikawa M, Hosogoe S, Tokui N, Yamamoto H, Narita S, Ito H, Yoneyama T, Hashimoto Y, Kawaguchi T, Habuchi T, Ohyama C. Tanaka T, et al. Among authors: kido k. Int J Urol. 2020 Dec;27(12):1095-1100. doi: 10.1111/iju.14363. Epub 2020 Sep 6. Int J Urol. 2020. PMID: 32893401
Preoperative chronic kidney disease predicts poor oncological outcomes after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma.
Kodama H, Hatakeyama S, Fujita N, Iwamura H, Anan G, Fukushi K, Narita T, Tanaka T, Kubota Y, Horiguchi H, Momota M, Kido K, Matsumoto T, Soma O, Hamano I, Yamamoto H, Tobisawa Y, Yoneyama T, Yoneyama T, Hashimoto Y, Koie T, Ito H, Yoshikawa K, Sasaki A, Kawaguchi T, Sato M, Ohyama C. Kodama H, et al. Among authors: kido k. Oncotarget. 2017 Aug 24;8(47):83183-83194. doi: 10.18632/oncotarget.20554. eCollection 2017 Oct 10. Oncotarget. 2017. PMID: 29137333 Free PMC article.
Detecting asymptomatic recurrence after radical nephroureterectomy contributes to better prognosis in patients with upper urinary tract urothelial carcinoma.
Horiguchi H, Hatakeyama S, Anan G, Kubota Y, Kodama H, Momota M, Kido K, Yamamoto H, Tobisawa Y, Yoneyama T, Yoneyama T, Hashimoto Y, Koie T, Ito H, Yoshikawa K, Kawaguchi T, Sato M, Ohyama C. Horiguchi H, et al. Among authors: kido k. Oncotarget. 2018 Jan 4;9(9):8746-8755. doi: 10.18632/oncotarget.23982. eCollection 2018 Feb 2. Oncotarget. 2018. PMID: 29492234 Free PMC article.
Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N, Hatakeyama S, Momota M, Kido K, Narita T, Tobisawa Y, Yoneyama T, Yamamoto H, Imai A, Ito H, Yoneyama T, Hashimoto Y, Yoshikawa K, Ohyama C. Fujita N, et al. Among authors: kido k. Urol Oncol. 2020 Aug;38(8):684.e17-684.e24. doi: 10.1016/j.urolonc.2020.03.009. Epub 2020 Apr 9. Urol Oncol. 2020. PMID: 32278732
361 results